The Trump Administration is relying mainly on administrative action to advance its prescription drug pricing agenda because it has not received much help from Congress, but the limitations of that approach are beginning to show.
HHS Secretary Alex Azar, as he unveiled the Administration’s “Blueprint” of policies to lower prices last spring, touted the “power...